182 related articles for article (PubMed ID: 25691281)
1. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):853-7. PubMed ID: 23306309
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer.
Ohnuma H; Sato Y; Hirakawa M; Okagawa Y; Osuga T; Hayashi T; Sato T; Miyanishi K; Kobune M; Takimoto R; Sagawa T; Hori M; Someya M; Nakata K; Sakata K; Takayama T; Kato J
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):382-90. PubMed ID: 26232855
[TBL] [Abstract][Full Text] [Related]
8. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
9. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Akutsu Y; Shuto K; Kono T; Uesato M; Hoshino I; Shiratori T; Miyazawa Y; Isozaki Y; Akanuma N; Matsubara H
Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Yamasaki M; Miyata H; Tanaka K; Shiraishi O; Motoori M; Peng YF; Yasuda T; Yano M; Shiozaki H; Mori M; Doki Y
Oncology; 2011; 80(5-6):307-13. PubMed ID: 21778771
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
[TBL] [Abstract][Full Text] [Related]
12. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
Gong Y; Ren L; Zhou L; Zhu J; Huang M; Zhou X; Wang J; Lu Y; Hou M; Wei Y
Cancer Chemother Pharmacol; 2009 Jul; 64(2):327-33. PubMed ID: 19048253
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
Cancer Chemother Pharmacol; 2015 Mar; 75(3):449-55. PubMed ID: 25544126
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
16. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Fujita Y; Hiramatsu M; Kawai M; Sumiyoshi K; Nishimura H; Tanigawa N
Dis Esophagus; 2008; 21(6):496-501. PubMed ID: 18840134
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
20. Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study.
Yamashita H; Omori M; Takenaka R; Okuma K; Kobayashi R; Ohtomo K; Nakagawa K
Radiother Oncol; 2014 Nov; 113(2):182-7. PubMed ID: 25466372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
